Compare Abbott Laboratories (ABT) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Brookfield Infrastructure Partners LP — how do they compare? Abbott Laboratories trades at $95.76 (market cap $166.94B), while Brookfield Infrastructure Partners LP trades at $36.86 (market cap $16.97B). The key difference: Abbott Laboratories is far larger — about 9.8× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.94%). Which is the better fit depends on your goals.
| ABT | BIP | |
|---|---|---|
Market Cap | $166.94B | $16.97B |
Sector | Health | Industrials |
52-Week High | $136.62 | $40.08 |
52-Week Low | $82.57 | $29.81 |
Enterprise Value | $193.69B | $78.64B |
Dividend Yield | 2.63% | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Brookfield Infrastructure Partners (BIP) trades at $37.31, up 0.81% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock carries a high P/E of 56.53 but attractive P/S of 0.71 and EV/EBITDA of 7.53. Recent earnings show volatility with two misses in the last three quarters, though Q2 2026 results are pending. The company maintains strong cash flow from operations of $6.0 billion and recently declared a $0.46 dividend.
BIP offers value through its discounted valuation and 5% yield, supported by inflation-linked contracts and infrastructure assets. However, risks include recent earnings misses, high debt levels, and sensitivity to interest rates. Analyst consensus is strongly bullish with a $45.50 price target, suggesting 22% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
